Vertex is already looking beyond the triple therapy concept, towards a Gene Editing mRNA drug, which it says could help the entire global population of CF patients, which is up to 75,000 patients ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

I am not a biotech expert, but I could not ignore the strength of Vertex's CF drug portfolio in 2022. The stock has almost doubled since then. While continuing to invest in innovative CF ...

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

While UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug has received a label extension from the European Commission allowing it to be used in younger ...

Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be ...

Today, Vertex’s portfolio of blockbuster CF products spans multiple drugs and drug combinations that can treat 90% of CF patients. CEO Reshma Kewalramani says Vertex aims to eventually reach all ...

Shwetha Sree, left, with her 5-year-old son Vihaan, who has cystic fibrosis. He would be eligible for Vertex’s drug on his 6th birthday were he to live in the U.S. Credit...Atul Loke for The New ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has been granted FDA priority review for its investigational once-daily vanza triple combination treatment for cystic fibrosis, with a target action date set ...

(Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta. However, the drugmaker ...

May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF ...